T CELL DEPLETION WITH CAMPATH-1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION
- 1 April 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 45 (4) , 753-758
- https://doi.org/10.1097/00007890-198804000-00018
Abstract
A total of 282 patients with leukemia have been treated by transplantation from HLA-matched siblings using marrow depleted of T cells with CAMPATH-1 and autologous complement. The incidence of graft-versus-host disease (GVHD) of grades 2-4 was only 12% but the maximum incidence of graft failure was 15%. A significant increase in relapse cannot yet be detected in acute leukemia but relapse in chronic granulocytic leukemia (CGL) was substantially above that reported before T cell depletion. The most important predictive factor for relapse in CGL appeared to be slow engraftment. This finding suggests an alternative explanation for the graft-versus-leukemia effect other than a direct attack on leukemia cells. This is that donor T cells may affect the balance of competition between donor and recipient haemopoesis by preventing a rejection reaction to donor stem cells. Recipient leukemic cells would benefit (i.e. relapse) if recipient hemopoiesis gained an advantage. If this explanation were true we would expect extra immunosuppressive preconditioning of recipients to reduce the incidence of relapse, as well as preventing graft rejection.This publication has 30 references indexed in Scilit:
- Marrow Transplantation for the Treatment of Chronic Myelogenous LeukemiaAnnals of Internal Medicine, 1986
- Bone marrow transplantation for acute nonlymphoblastic leukaemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.)British Journal of Haematology, 1984
- DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTSThe Lancet, 1984
- ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIAThe Lancet, 1984
- REMOVAL OF T-CELLS FROM BONE-MARROW FOR TRANSPLANTATION - A MONOCLONAL ANTI-LYMPHOCYTE ANTIBODY THAT FIXES HUMAN-COMPLEMENT1983
- ELIMINATION OF CARCINOMA CELLS FROM HUMAN BONE MARROWThe Lancet, 1982
- BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN FIRST REMISSIONThe Lancet, 1982
- Factors controlling the engraftment of transplanted dog bone marrow cellsTissue Antigens, 1982
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977